|
1
|
Hughes JP, Rees S, Kalindjian SB and
Philpott KL: Principles of early drug discovery. Br J Pharmacol.
162:1239–1249. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: In vitro assays and techniques utilized in anticancer drug
discovery. J Appl Toxicol. 39:38–71. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Pushpakom S, Iorio F, Eyers PA, Escott KJ,
Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et
al: Drug repurposing: Progress, challenges and recommendations. Nat
Rev Drug Discov. 18:41–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Marrs JC and Anderson SL: Bempedoic acid
for the treatment of dyslipidemia. Drugs Context.
9(2020-6-5)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ray KK, Bays HE, Catapano AL, Lalwani ND,
Bloedon LT, Sterling LR, Robinson PL and Ballantyne CM: CLEAR
Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL
cholesterol. N Engl J Med. 380:1022–32. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Feng X, Zhang L, Xu S and Shen AZ:
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis:
An updated review. Prog Lipid Res. 77(101006)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Emerging role of histone deacetylase inhibitors as
anti-breast-cancer agents. Drug Discov Today. 24:685–702.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hatchwell E and Greally JM: The potential
role of epigenomic dysregulation in complex human disease. Trends
Genet. 23:588–95. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ediriweera MK and Cho SK: Targeting miRNAs
by histone deacetylase inhibitors (HDACi): Rationalizing
epigenetics-based therapies for breast cancer. Pharmacol Ther.
206(107437)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pulya S, Amin SA, Adhikari N, Biswas S,
Jha T and Ghosh B: HDAC6 as privileged target in drug discovery: A
perspective. Pharmacol Res. 163(105274)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Batchu SN, Brijmohan AS and Advani A: The
therapeutic hope for HDAC6 inhibitors in malignancy and chronic
disease. Clinical Sci. 130:987–1003. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Waldecker M, Kautenburger T, Daumann H,
Busch C and Schrenk D: Inhibition of histone-deacetylase activity
by short-chain fatty acids and some polyphenol metabolites formed
in the colon. J Nutr Biochem. 19:587–593. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Oniciu DC and Myers JL: Bempedoic acid and
the fraudulent fatty acid family: The gold rush to cardiovascular
therapies in the new millennium. Org Process Res Dev. 25:365–372.
2021.
|
|
15
|
Ediriweera MK, To NB, Lim Y and Cho SK:
Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6)
inhibitors. Biochimie. 186:147–156. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tian W, Chen C, Lei X, Zhao J and Liang J:
CASTp 3.0: Computed atlas of surface topography of proteins.
Nucleic Acids Res. 46:W363–W367. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Laskowski RA and Swindells MB: LigPlot+:
Multiple ligand-protein interaction diagrams for drug discovery. J
Chem Inf Model. 51:2778–2786. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Osko JD and Christianson DW: Structural
determinants of affinity and selectivity in the binding of
inhibitors to histone deacetylase 6. Bioorg Med Chem Lett.
30(127023)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Osko JD and Christianson DW: Structural
basis of catalysis and inhibition of HDAC6 CD1, the enigmatic
catalytic domain of histone deacetylase 6. Biochemistry.
58:4912–4924. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ho RH, Chan JC, Fan H, Kioh DY, Lee BW and
Chan EC: In silico and in vitro interactions between short chain
fatty acids and human histone deacetylases. Biochemistry.
56:4871–4878. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fass DM, Shah R, Ghosh B, Hennig K, Norton
S, Zhao WN, Reis SA, Klein PS, Mazitschek R, Maglathlin RL, et al:
Effect of inhibiting histone deacetylase with short-chain
carboxylic acids and their hydroxamic acid analogs on vertebrate
development and neuronal chromatin. ACS Med Chem Lett. 2:39–42.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gilbert KM, DeLoose A, Valentine JL and
Fifer EK: Structure-activity relationship between carboxylic acids
and T cell cycle blockade. Life Sci. 78:2159–2165. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Han R, Yang H, Li Y, Ling C and Lu L:
Valeric acid acts as a novel HDAC3 inhibitor against prostate
cancer. Medical Oncol. 39(213)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Markham A: Bempedoic acid: First approval.
Drugs. 80:747–753. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Esperion Therapeutics Inc.: NEXLETOL
(bempedoic acid): tablets, for oral use. Initial U.S. Approval:
2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf.
Accessed December 12, 2022.
|
|
26
|
Rose A, Rodriguez-Aguilera JR, Schicht G,
Lohrenz A, Tvardovskiy A, Büscher J, Hoffmann A, Damm G, Laufs U,
Seehofer D, et al: The impact of cholesterol lowering drugs on
metabolism and epigenetics. Atherosclerosis. 355:179–180. 2022.
|
